Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Surface Oncology Inc. logo — #lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #Bo...

Surface Oncology Inc.

#lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2022,2021

Founded 2014 United States Cambridge, United States 14 employees Post Ipo Equity Total: $88.90M Biotechnology, Health Care +1

General Information

Company Name Surface Oncology Inc.
Founded Year 2014
Location United States Cambridge, United States +1
Employees 14
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Post Ipo Equity
Social

Get notified when Surface Oncology Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Surface Oncology Inc.

Surface Oncology Inc. is a clinical-stage immuno-oncology company that was founded in 2014. The company is headquartered in the United States and has recently received a significant $28.90MPost-IPO Equity investment on 20 May 2020 from BVF Partners, EcoR1 Capital, Venrock Healthcare Capital Partners, RS Investments. Surface Oncology is dedicated to leveraging its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) to develop next-generation therapies for cancer patients. The company's focus on the development of a broader, more multi-faceted therapeutic approach represents a significant leap forward in immuno-oncology research. The company's diverse clinical and preclinical pipeline of immune-enhancing antibody candidates targets the innate and adaptive arms of the immune system. This approach is aimed at delivering dramatically different therapies for patients and their families by addressing the limitations of current first-generation immunotherapies. Surface Oncology aims to convert patients’ non-responsive ‘cold’ tumors into immune-active ones by leveraging its deep understanding of TME biology to target factors and cells that suppress the anti-tumor immune response. The company's emphasis on breaking through across all dimensions of its work reflects its commitment to delivering transformative outcomes for cancer patients. In terms of discovery, Surface Oncology utilizes its world-class Scientific Advisory Board (SAB) to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies. This approach generates therapeutic-quality antibodies and unique tools for exploring the biology of the tumor microenvironment. With its strong focus on addressing the limitations of current immunotherapies and a commitment to pushing the boundaries of immuno-oncology research, Surface Oncology is well-positioned to make a significant impact in the treatment of cancer.

Taxonomy: immuno-oncology, cancer therapy, TME biology, immune system, antibody candidates, cancer research, novel immunotherapy targets, tumor microenvironment, immune evasion, biological pathways, clinical-stage, cancer treatments, scientific founders, biological research

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 4
Investor Investor
•••• •••• 		20 May 2020
Debt Financing •••••• 1
Investor
25 Nov 2019
Series A •••••• 5
Investor Investor Investor Investor
•••• •••• 		08 Jan 2015
Seed Round •••••• - 01 Sep 2014

Surface Oncology Inc. Alternatives & Competitors

Surface Oncology Inc. vs
TME Pharma
TME Pharma Germany

Developing novel therapies for treatment of the most aggressive cancers by acting on the tumor micro...

Post Ipo Equity
12 employees
Biotechnology, Health Care
Surface Oncology Inc. vs
Nonagen Therapeutics Corporation
Nonagen Therapeutics Corporation United States

Our mission is to discover and develop breakthrough therapeutics for human diseases

2 employees
Biotechnology
Surface Oncology Inc. vs
Incendia Therapeutics
Incendia Therapeutics United States

Breaking Barriers to Better Cancer Treatment

Series A
24 employees
Biotechnology, Health and Wellness

FAQ About Surface Oncology Inc.

#lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2022,2021
Surface Oncology Inc. was founded in 2014.
Surface Oncology Inc. is headquartered in Cambridge, United States.
Surface Oncology Inc. operates in the following industries: Biotechnology, Health Care, Life Sciences.
Surface Oncology Inc. has approximately 14 employees.
Surface Oncology Inc. has completed 4 funding rounds, raising a total of $88.90M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Surface Oncology Inc. include TME Pharma, Nonagen Therapeutics Corporation, Incendia Therapeutics, iTeos Therapeutics, Compass Therapeutics Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Surface Oncology Inc. and TME Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Surface Oncology Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy